2 results
Approved WMOPending
The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.
Approved WMOCompleted
Primary:To evaluate the feasibility and safety of intra-tumour and peri-tumour therapy with GMP hBMP4 in increasing doses in patients with progressive and/or multiple recurrent GBM, identify DLT, and to determine whether there is a maximum tolerated…